Salute e Benessere

PCI Biotech: Employee share option scheme

In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech's choice), at a strike price of NOK 1.81, equal to the volume weighted average share price (VWAP)...
Nasdaq GlobeNewswire
02/09/2024

Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study…

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, tolebrutinib met the primary endpoint in delaying time to onset of confirmed disability progression in people with nrSPMS, a population for which there are currently no approved therapies and significant unmet medical needThe GEMINI 1 and 2 studies evaluating tolebrutinib in...
Nasdaq GlobeNewswire
02/09/2024

New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

The results revealed several important findings: The results revealed several important findings: Dr. Janakan Krishnarajah, Chief Operating Officer and Chief Medical Officer of iX Biopharma, said: "This study's findings provide strong evidence that our innovative sublingual freeze-dried technology delivers NAD+ rapidly into plasma and then directly into cells, challenging the previously held belief that its large size prevents cellular penetration. Along with the positive data from…
PR Newswire
02/09/2024

LG PRESENTS NEW APPLIANCE LINEUP WITH INDUSTRY-LEADING ENERGY EFFICIENCY AT IFA…

Industry-Leading Energy Efficiency with AI-Enhanced Laundry SolutionsLG's latest washing machine and dryer set new standards for energy efficiency. The washing machine is able to perform a new drum motion that helps deliver clean laundry while minimizing the energy consumption of its Artificial Intelligence Direct Drive (AI DD™) motor. The washer intelligently adjusts the motor's RPM in real-time, contributing to the appliance's impressive A-55 percent energy rating1 and preventing laundry from…
PR Newswire
02/09/2024

Avance Clinical GlobalReady Site Partnership Network Expands Rapidly to 2,000…

GlobalReady Site Partnership Network. Avance Clinical CEO, Yvonne Lungershausen said these 2,000 highly qualified sites further enhanced delivery of unprecedented efficiency and effectiveness for our biotech clients during their clinical development.Tina Schied, Avance Clinical's US-based Senior Site Specialist said the team has individually reviewed these sites for quality, therapeutic area expertise, advanced processes, and compliance so our clients can be assured of quality, rapid...
Nasdaq GlobeNewswire
01/09/2024

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief…

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural history study of Stargardt diseaseSAN DIEGO, Sept.01, 2024(GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced...
Nasdaq GlobeNewswire
01/09/2024

Junshi Biosciences Announces 2024 Interim Financial Results and Provides…

FINANCIAL HIGHLIGHTSAs of June 30, 2024, the total revenue of Junshi Biosciences was approximately RMB786 million during the first half of 2024, representing an increase of approximately 17% compared to 2023. The growth was mainly due to the approximately 11% increase in revenue from pharmaceutical products compared to 2023. In particular, the domestic sales revenue of our core product, TUOYI ®(toripalimab), reached approximately RMB671 million, representing an increase of...
Nasdaq GlobeNewswire
31/08/2024

Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by…

Key Takeaways from the Anti-Infective Drugs Market Report Key Takeaways from the Anti-Infective Drugs Market Report To read more about the latest highlights related to the anti-infective drugs market, get a snapshot of the key highlights entailed in theGlobal Anti-Infective Drugs Market Report Anti-Infective Drugs Overview Anti-infective drugs are a broad category of medications designed to combat infections caused by pathogens such as bacteria, viruses, fungi, and parasites...
PR Newswire
30/08/2024

ALK Inhibitors Market: A Comprehensive Overview of Current Trends and Future…

Key Takeaways from the ALK Inhibitors Market Report Key Takeaways from the ALK Inhibitors Market Report Discover which therapies are expected to grab the ALK inhibitors market share @ALK Inhibitors Market Report ALK Inhibitors Market Dynamics The market dynamics for ALK inhibitors have been evolving rapidly, driven by significantadvances in cancer treatment and the growing prevalence of ALK-positive cancers, particularly NSCLC. One of the primary drivers of the ALK...
PR Newswire
30/08/2024

Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for…

"Today's authorization enables Novavax to launch our updated COVID-19 vaccine in the U.S. in pre-filled syringes, and we have worked hard to ensure consumers have access in thousands of locations nationwide," said John C. Jacobs, President and Chief Executive Officer, Novavax. "Our updated vaccine targets JN.1, the 'parent strain' of currently circulating variants, and has shown robust cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1 and LB.1."…
PR Newswire
30/08/2024

Transactions in Zealand Pharma shares and/or related securities by persons…

Company announcement – No. 43 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, August 30, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or...
Nasdaq GlobeNewswire
30/08/2024

Fagron's share buy-back program: Weekly update

Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET Fagron's share buy-back program: Weekly update In the period from 26 August 2024 through 30 August 2024, Fagron purchased 37,000 of its own shares at an average price of € 18.99 per share corresponding to a total amount of € 1,357,476.41. These purchases are part of the share buy-back program of up to 150,000 Fagron shares to fulfill Fagron's obligations under its long-term incentive scheme,...
Nasdaq GlobeNewswire
30/08/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 30082024_trading_in_shares_PRM
Nasdaq GlobeNewswire
30/08/2024

Total number of shares and voting rights in Zealand Pharma on August 30, 2024

Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Copenhagen, Denmark, August 30, 2024–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the...
Nasdaq GlobeNewswire
30/08/2024

Momcozy Concludes Successful Breastfeeding Month Campaign: 'Breaking…

At the heart of the campaign was the offline bus tour in partnership with Pumpspotting on Barb the Breast Express. This tour made multiple stops in communities, facilitating direct interactions with mothers. Discussions on breastfeeding challenges, giveaways, and engaging activities were organized to support and uplift mothers along their journeys. At the heart of the campaign was the offline bus tour in partnership with Pumpspotting on Barb the Breast Express. This tour made multiple stops…
PR Newswire
30/08/2024

Bioactive Dressings Market worth $5.8 billion by 2029 driven by Increasing Tech…

Browse in-depth TOC on "Bioactive Dressings Market" Browse in-depth TOC on "Bioactive Dressings Market" 439 - Tables57 - Figures343 - Pages Smith+Nephew: Global Leader in Bioactive Dressings Smith+Nephew (UK) held the top position in the bioactive dressings market in 2023, driven by a robust global distribution network acrossNorth America,Europe,Asia Pacific,Latin America, theMiddle East, andAfrica. This wide geographical presence enables the company...
PR Newswire
30/08/2024

Coloplast A/S - Trading in Coloplast shares by board members, executives or…

Please see enclosed pdf. Attachment 30082024_trading_in_shares_ARA
Nasdaq GlobeNewswire
30/08/2024

Eureka Unveils the E20 Plus with Advanced Cleaning Performance and Obstacle…

The Eureka E20 Plus continues the innovative design of the E10s. Unlike traditional robotic vacuums with base stations, the Eureka E20 Plus features a bag-free base station. After cleaning, the base station collects debris in a dust cup, much like most cordless vacuums. When the dust cup is full, press a button to empty it, and users are ready for the next cleaning session, saving both money and time. The Eureka E20 Plus continues the innovative design of the E10s. Unlike traditional robotic...
PR Newswire
30/08/2024

Trading by management and close relations of management

Please read the full announcement in PDFAttachment 2024_29_Trading_By_Management
Nasdaq GlobeNewswire
30/08/2024

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 30 August 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
30/08/2024

Ibuprofen Market to Reach $213.6 Million, Globally, by 2033 at 7.9% CAGR: Allied…

The global ibuprofen market is experiencing growth due to widespread adoption of the nonsteroidal anti-inflammatory drug such as ibuprofen for pain management, rise in geriatric population, and surge in prevalence of chronic disease. Furthermore, the availability of over-the-counter ibuprofen is expected to further increase the adoption of ibuprofen among its users. The global ibuprofen market is experiencing growth due to widespread adoption of the nonsteroidal anti-inflammatory drug such as...
PR Newswire
30/08/2024

ZINZINO AB (PUBL): INTERIM REPORT SECOND QUARTER 2024

Revenues in the second quarter of 2024 amounted to SEK 507.0 (407.9) million, corresponding to 24% (24%) growth compared to the corresponding period last year. EBITDA increased to SEK 63.0 (53.7) million, and the EBITDA margin amounted to 12.4% (13.2%). During the quarter, Zinzino acquired the rights to Luxembourg-based Xelliss SA distributor database, inventory and IP assets, acquired 49% of the shares in the Cypriot olive oil producer Cleanthi Alpha-Olenic LTD and signed a letter of intent to…
PR Newswire
30/08/2024

Global Vaccine Adjuvants Market to Show Remarkable Growth at a CAGR of ~13% by…

Key Takeaways from the Vaccine Adjuvants Market Report Key Takeaways from the Vaccine Adjuvants Market Report To read more about the latest highlights related to the vaccine adjuvants market, get a snapshot of the key highlights entailed in the Global Vaccine Adjuvants Market Report Vaccine Adjuvants Overview Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the primary antigen. By stimulating the immune system more effectively,...
PR Newswire
29/08/2024

Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options

Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a "Common Share"); and (ii) one (1) common share purchase warrant (each a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at a price ofC$0.32for a period of four (4) years from the date of issuance. Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes. The securities issued to Canadian subscribers…
PR Newswire
29/08/2024
Altri  Comunicati